MARKET

SGMO

SGMO

Sangamo Therapeutics Inc
NASDAQ
0.4959
-0.0342
-6.45%
After Hours: 0.4974 +0.0015 +0.30% 19:59 12/05 EST
OPEN
0.5280
PREV CLOSE
0.5301
HIGH
0.5280
LOW
0.4908
VOLUME
5.02M
TURNOVER
--
52 WEEK HIGH
2.840
52 WEEK LOW
0.3846
MARKET CAP
166.87M
P/E (TTM)
-1.1199
1D
5D
1M
3M
1Y
5Y
1D
BUZZ-U.S. STOCKS ON THE MOVE-CrowdStrike Holdings, Procter & Gamble, Ford Motor
Reuters · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Cloudflare, Boeing
Reuters · 4d ago
BUZZ-Sangamo jumps as US FDA fast-tracks drug for chronic nerve pain
Reuters · 4d ago
Sangamo rises as FDA grants Fast Track status to neuropathic pain asset
Seeking Alpha · 4d ago
Sangamo receives U.S. FDA Fast Track Designation to ST-503
TipRanks · 5d ago
SANGAMO THERAPEUTICS RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR ST-503 FOR THE TREATMENT OF SMALL FIBER NEUROPATHY
Reuters · 5d ago
SANGAMO THERAPEUTICS INC - EXPECTS TO DOSE FIRST PHASE 1/2 STAND STUDY PATIENT IN THE COMING MONTHS
Reuters · 5d ago
Weekly Report: what happened at SGMO last week (1124-1128)?
Weekly Report · 6d ago
More
About SGMO
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.

Webull offers Sangamo Therapeutics Inc stock information, including NASDAQ: SGMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGMO stock methods without spending real money on the virtual paper trading platform.